ID | 1046 |
Name of the vaccine | Quadracel |
Microbe | Bacteria |
Disease name | Pertussis (Whooping Cough) |
Name of bacteria | Bordetella pertussis |
Type of vaccine | Inactivated |
Nucleic acid content | DNA |
Age | 4 to 6 years |
Description of the vaccine | Diphtheria, Tetanus Toxoids, Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine (DTaP vaccine). |
Name of the manufacturer | Sanofi Pasteur Limited |
Name of the manufacturing country | Canada |
Year of manufacture | 2015 |
Clinical Phase status | Approved |
Bacterial strain | Gram-negative coccobacillus. |
Efficacy | Prevent pertussis in infants with a protective efficacy of 85.2% using the WHO case definition and the protective efficacy against mild disease was 77.9%. |
Vaccine formulation | Suspension for injection |
Dosage | Single dose of 0.5 mL. |
Mechanism of action | Not clearly defined. |
Route of administration | Intramuscular |
Indications | If Quadracel is administered to immunocompromised persons the expected immune response may not be obtained. |
Export | Distributed by- Sanofi Pasteur Inc., USA |
Approval | US FDA |
Adjuvant | Aluminium phosphate |
Repurposing | For diphtheria, tetanus and poliovirus. |
Side effects of vaccine | Pain, increase in arm circumference, erythema, swelling, myalgia, malaise, and headache. |
Post vaccination | NA |
Dose type | Single dose |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NA |
Reference | https://www.fda.gov/media/91640/download |
Other name | NA |
Additional Links | https://products.sanofi.ca/en/quadracel.pdf
|